The ONE blog features an interview with Esteban Burrone, head of policy for the Medicines Patent Pool, who discusses how antiretroviral drugs used to treat HIV became less expensive over the past decade, allowing for millions more people living with the virus to receive treatment. Burrone says partnerships with pharmaceutical companies have been key in reducing the cost of treatment, and he adds, “Our focus is now on drugs under development and second- and third-line medicines, which patients need when they develop resistance” (7/23).